Interactions of enantiomers of 2′,3′-didehydro-2′,3′-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase

Antiviral Research

Volumn 56, Issue 3, 2002, Pages 189-205

  Ray, Adrian S ^a   Murakami, Eisuke ^a   Peterson, Celeste N ^a   Shi, Junxing ^b   Schinazi, Raymond F ^b   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral agents; Molecular modeling; Nucleoside inhibitors; Transient kinetics

Indexed keywords

ELVUCITABINE; EMTRICITABINE; LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; VALINE;

ANTIVIRAL ACTIVITY; ARTICLE; COMPUTER MODEL; CROSS RESISTANCE; DRUG POTENCY; ENANTIOMER; FLUORINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STEADY STATE; STEREOCHEMISTRY; STEREOSPECIFICITY;

BASE SEQUENCE; BINDING SITES; CYTIDINE TRIPHOSPHATE; DEOXYCYTOSINE NUCLEOTIDES; HIV-1 REVERSE TRANSCRIPTASE; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; ZALCITABINE;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036888501     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00102-X     Document Type: Article

References (50)

1. Chou K.M., Kukhanova M., Cheng Y.C. A novel action of human apurinic/apyrimidinic endonuclease. Excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J. Biol. Chem. 275:2000;31009-31015.
2. De Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38:1995;2491-2517.
3. De Clercq E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 10:1997;674-693.
4. De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int. J. Antimicrob. Agents. 12:1999;81-95.
5. Delaney W.E. IV, Locarnini S., Shaw T. Resistance of hepatitis B virus to antiviral drugs; current aspects and directions for future investigation. Antiviral Chem. Chemother. 12:2001;1-35.
6. Dutschman G.E., Bridges E.G., Liu S.-H., Gullen E., Guo X., Kukhanova M., Cheng Y.-C. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5- fluorocytidine and its activity in combination with clinically approved anti-human imunodeficiency virus β-D(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother. 42:1998;1799-1804.
7. Feng J.Y., Anderson K.S. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TC-TP by HIV-1 reverse transcriptase. Biochemistry. 38:1999a;55-63.
8. Feng J.Y., Anderson K.S. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry. 38:1999b;9440-9448.
9. Feng J.Y., Shi J., Schinazi R.F., Anderson K.S. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J. 13:1999;1511-1517.
10. Ford H., Dai F., Mu L., Siddiqui M.A., Nicklaus M.C., Anderson L., Marquez V.E., Barchi J.J. Adenosine deaminase prefers a distinct sugar ring conformation for binding and catalysis: kinetic and structural studies. Biochemistry. 39:2000;2581-2592.
11. Fu L., Liu S.H., Cheng Y.C. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem. Pharmacol. 57:1999;1351-1359.
12. Furman P.A., Davis M., Liotta D.C., Paff M., Frick L.W., Nelson D.J., Dornsife R.E., Wurster J.A., Wilson L.J., Fyfe J.A., Tuttle J.V., Miller W.H., Condreay L., Averett D.R., Schinazi R.F., Painter G.R. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:1992;2686-2692.
13. Gao H.Q., Boyer P.L., Sarafianos S.G., Arnold E., Hughes S.H. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Mol. Biol. 300:2000;403-418.
14. Harte W.E. Jr., Starrett J.E. Jr., Martin J.C., Mansuri M.M. Structural studies of the anti-HIV agent 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T). Biochem. Biophys. Res. Commun. 175:1991;298-304.
15. Huang H., Verdine G.L., Chopra R., Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for nucleoside analog drug resistance. Science. 282:1998;1669-1675.
16. Jarvis B., Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. published erratum appears in Drugs 1999 Oct; 58 (4): 587 Drugs. 58:1999;101-141.
17. Kati W.M., Johnson K.A., Jerva L.F., Anderson K.S. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:1992;25988-25997.
18. Kerr S.G., Anderson K.S. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry. 36:1997a;14064-14070.
19. Kerr S.G., Anderson K.S. RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates. Biochemistry. 36:1997b;14056-14063.
20. Kool E.T. Replication of non-hydrogen bonded bases by DNA polymerases: a mechanism for steric matching. Biopolymers (Nucleic Acid Science). 48:1998;3-17.
21. Krayevsky A.A., Watanabe K.A. Substrates of DNA polymerases with planar conformation of sugar: model of substrate transition state? Nucleosides and Nucleotides. 17:1998;1153-1162.
22. Kukhanova M., Li X., Chen S.H., King I., Doyle T., Prusoff W., Cheng Y.C. Interaction of beta-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design. Mol. Pharmacol. 53:1998;801-807.
23. Kukhanova M., Liu T.W., Pelicano H., Cheng Y.C. Excision of beta-L- and beta-D-nucleotide analogs from DNA by p53 protein. Nucleosides Nucleotides Nucleic Acids. 19:2000;435-446.
24. Larder B.A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Review J. Gen. Virol. 75:1994;951-957.
25. Lau D.T., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., Kleiner D.E., Schmid P., Condreay L.D., Gauthier J., Kuhns M.C., Jake Liang T., Hoofnagle J.H. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 32:2000;828-834.
26. Le Guerhier F., Pichoud C., Guerret S., Chevallier M., Jamard C., Hantz O., Li X.Y., Chen S.H., King I., Trepo C., Cheng Y.C., Zoulim F. Characterization of the antiviral effect of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 44:2000;111-122.
27. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 337:1997;1733-1745.
28. Lin P.F., Samanta H., Rose R., Patick A.K., Lee A., Anderson R.E., Colonno R.J. Genotypic and phenotypic analysis of HIV-1 virus isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170:1994;1157-1164.
29. Lin T.S., Luo M.Z., Liu M.C., Zhu Y.L., Gullen E., Dutschman G.E., Cheng Y.C. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-cytidine (beta-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-beta-L-5-fluorocytidine (beta-L-FD4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39:1996;1757-1759.
30. Mitsuya H., Yarchoan R., Kageyama S., Broder S. Targeted therapy of human immunodeficiency virus-related disease. FASEB J. 5:1991;2369-2381.
31. Parker W.B., Cheng Y.-C. Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 6:1994;57-61.
32. Pelicano H., Kukhanova M., Cheng Y.C. Excision of b-D- and b-L-nucleotide analogs from DNA by the human cytosolic 3(-to-5( exonuclease. Mol. Pharmacol. 57:2000;1051-1055.
33. Perry C.M., Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 53:1997;657-680.
34. Pottage, J., Thompson, M., Kahn, J., Delahanty, J., McCreedy, B., Rousseau, F., 1998. In: 12th World AIDS Conference in Geneva.
35. Ray A.S., Anderson K.S. Mechanistic studies to understand the inhibition of wild type and mutant HIV-1 reverse transcriptase by carbovir-triphosphate. Nucleosides Nucleotides Nucleic Acids. 20:2001;1247-1250.
36. Ray A.S., Yang Z., Shi J., Hobbs A., Schinazi R.F., Chu C.K., Anderson K.S. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry. 41:2002;5150-5162.
37. Rittinger K., Divita G., Goody R.S. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA. 92:1995;8046-8049.
38. Sarafianos S.G., Das K., Clark A.D. Jr., Ding J., Boyer P.L., Hughes S.H., Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. USA. 96:1999;10027-10032.
39. Schinazi R.F., Lloyd R.M. Jr., Nguyen M.H., Cannon D.L., McMillan A., Ilksoy N., Chu C.K., Liotta D.C., Bazmi H.Z., Mellors J.W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:1993;875-881.
40. Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P.A., Painter G., Choi W.-B., Liotta D.C. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:1992;2423-2431.
41. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., Collis P., Danner S.A., Mulder J., Loveday C., Christopherson C., Kwok S., Sninsky J., Boucher C.A.B. Rapid changes in human immunodeficiency virus type 1 RNA load and appearence of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1995;1411-1419.
42. Shi J., McAtee J.J., Schlueter Wirtz S., Tharnish P., Juodawlkis A., Liotta D.C., Schinazi R.F. Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. J. Med. Chem. 42:1999;859-867.
43. Skoog D.A., Leary J.J. Principles of Instrumental Analysis. 1992;Saunders College Publishing, New York.
44. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:1995;989-993.
45. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
46. Torresi J., Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 118:2000;S83-S103.
47. Vaccaro J.A., Parnell K.M., Terezakis S.A., Anderson K.S. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natrual substrate dTTP. Antimicrob. Agents Chemother. 44:1999;217-221.
48. Van Roey P., Pangborn W.A., Schinazi R.F., Painter G., Liotta D.C. Absolute configuration of the antiviral agent (-)-cis-5-fluoro-1-[2-hydroxymethyl)-1,3-oxanthiolan-5-yl]cytosine. Antiviral Chem. Chemother. 4:1993;369-375.
49. Wilson J.E., Aulabaugh A., Caligan B., McPherson S., Wakefield J.K., Jablonski S., Morrow C.D., Reardon J.E., Furman P.A. Human immunodeficiency virus type-1 reverse transcriptase. Contribution of Met-184 to binding of nucleoside 5′-triphosphate. J. Biol. Chem. 271:1996;13656-13662.
50. Zoulim F., Dannaoui E., Borel C., Hantz O., Lin T.S., Liu S.H., Trepo C., Cheng Y.C. 2′,3′-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40:1996;448-453.